For the management of migraine, potential protective factors may be equally important as trigger factors, but have been widely ignored. A study set up by Prof. Christian Wöber (Medical University of Vienna, Austria) and colleagues aimed to identify factors associated with decreased migraine attack risk in patients with migraine [1].
A total of 866 individuals with migraine registered to use N1-Headache®, a mobile app that connects patients to their clinicians and is specifically designed to identify migraine risk factors. Median age of participants was 43 years; 88% were women. In total, 88.7% had a diagnosis of migraine by a physician; 83% had episodic migraine; median number of migraine days was 8.8 per months; and 55.1% of women recorded at least one menstrual cycle. For 90 days, participants entered daily data about potential attack risk factors (e.g. diet, mood), migraine symptoms, and headache characteristics. A factor was defined as a potential protector if it was significantly associated with a decreased risk of migraine attack (unadjusted HR <1.0; P<0.05).
In 31.4% of patients no protectors were found, 65.9% had between 1 and 8 protectors, and 2.7% had 9 or more. The most common protectors were feeling refreshed after waking (32%), happiness (23%), good sleep quality (16%), being relaxed (13%), activity (9.0%), and coffee/caffeine (8.5%). Prof. Wöber stated that, similar to migraine triggers, migraine protectors are highly individual, and that behavioural factors are the most relevant protectors. Knowledge on these migraine ‘protectors’ may help patients adopt behavioural changes that may ultimately decrease migraine attack risk.
- Wöber C, et al. Potential migraine “protectors”: factors associated with decreased attack risk in individuals. OPR-069, EAN 2021 Virtual Congress, 19–22 June.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Eptinezumab shows acute benefits during migraine attack Next Article
Exploring the possibilities »
« Eptinezumab shows acute benefits during migraine attack Next Article
Exploring the possibilities »
Table of Contents: EAN 2021
Featured articles
Letter from the Editor
COVID-19
First evidence of brainstem involvement in COVID-19
Cognitive/behavioural alterations persistent after COVID-19
Neural base of persistent hyposmia after COVID-19
Neurological symptoms and complications of COVID-19 affect outcomes
Cerebrovascular Disease
Intracerebral haemorrhage only slightly increases mortality in COVID-19 patients
Stroke with covert brain infarction indicates high vascular risk
Expanding precision medicine to stroke care
Dexamethasone not indicated for chronic subdural haematoma
Cognitive Impairment and Dementia
Severe outcomes of COVID-19 in patients with dementia
Promising diagnostic accuracy of plasma GFAP
Sex modulates effect of cognitive reserve on subjective cognitive decline
Hypersensitivity to uncertainty in subjective cognitive decline
Epilepsy
Minimally invasive device to detect focal seizure activity
‘Mozart effect’ in epilepsy: why Mozart tops Haydn
Migraine and Headache
Factors associated with decreased migraine attack risk
Pregnant migraine patients at higher risk of complications
Occipital nerve stimulation in drug-resistant cluster headache
Rhythmicity in primary headache disorders
Multiple Sclerosis and NMOSD
Typing behaviour to remotely monitor clinical MS status
Alemtuzumab in treatment-naïve patients with aggressive MS
No higher early MS relapse frequency after stopping ponesimod
Good long-term safety and efficacy of inebilizumab in NMOSD
Neuromuscular Disorders
Inability to recognise disgust as first cognitive symptom of ALS
Pathogenic T-cell signature identified in myasthenia gravis
Parkinson’s Disease
Levodopa-carbidopa intestinal gel in patients with advanced PD
New Frontier – Navigated Transcranial Ultrasound
Exploring the possibilities
Related Articles
July 9, 2021
EAN 2021 Highlights Podcast
August 18, 2021
Safinamide improves non-motor symptoms in PD
August 18, 2021
24-month pooled FIREFISH data of risdiplam in SMA
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com